Exercise in a Pill Is Now in Human Trials - Summary - MDSpire

Exercise in a Pill Is Now in Human Trials

Atrogi's ATR-258 just dosed its first subjects — and the muscle data it's hunting could reframe how we treat weight loss.

  • By

  • Kerri Miller

  • March 18, 2026

  • 2 min

Share

Objective:

To evaluate the effects of ATR-258, a compound designed to replicate the metabolic benefits of exercise, in human subjects.

Approach:
    Key Findings:
    • Safety and tolerability were established in a previous Phase 1 trial with 69 subjects.
    • The current trial aims to gather data on muscle physiology, including biopsies and functional measures.
    Interpretation:

    ATR-258 targets muscle-sparing weight loss, addressing a gap left by GLP-1 treatments focused primarily on obesity.

    Limitations:
    • The study is limited to overweight men and has a narrow 8-week duration.
    • Generalizability and long-term metabolic outcomes are yet to be determined.
    Conclusion:

    ATR-258 could be significant in addressing muscle loss during weight loss, with results expected later this year.

    Sources:

Original Source(s)

Exercise in a Pill Is Now in Human Trials

  • by Kerri Miller

  • March 18, 2026

Related Content

GLP-1 Drugs Tied to Smell, Taste Changes

A matched electronic health record study of more than 876,000 patients with type 2 diabetes found a low absolute incidence but higher relative hazard of documented smell and taste disturbances among patients prescribed glucagon-like peptide-1 receptor agonists.

Medical Oddities: Gummies Good for the Gums

From gummies to hookworms, trackers to vibrating pills, medicine took some unexpected turns this week.

FDA Approves New Treatment for Thyroid Eye Disease

Phase 3 THRIVE and THRIVE-2 trials supported approval following improvements in proptosis and diplopia in active and chronic disease.